ELTX

1.4503.33%
CG

Carol Gail Ashe

Independent Director

Ms. Carol Gail Ashe, J.D., has been the Chief Business Officer at the New York Genome Center since 2014. Ms. Ashe is responsible for identifying and executing on revenue generating business development opportunities. She served as Vice President of Corporate Development for the Endo Pharmaceuticals pharmaceutical branded, generic and platform drug delivery pharmaceutical business units from 2011 to 2013. Ms. Ashe led the evaluation, structuring and negotiation of business development transactions for Endo’s branded, generic and platform drug delivery business units. She is an accomplished executive leader with extensive experience in corporate, legal, business development and venture capital in the pharmaceutical and biotech industries. In this capacity, she has a depth and breadth of transactional expertise in negotiating and structuring transactions involving academic institutions and biotech and pharmaceutical companies of all stages, including acquisitions, joint venture agreements, R&D collaborations and in-license agreements, among others. She was a Partner at SR One, the corporate venture capital fund of GlaxoSmithKline (“GSK”) from 2008 to 2010. She was the head of GSK’s US Corporate Legal Group supporting US-based mergers, acquisitions and equity investments from 2007 to 2008. Prior to that, Ms. Ashe led GSK’s global Business Development Transactions Legal Team supporting both the pharmaceutical and consumer healthcare business units from 1995 to 2007. She joined firm on January 2, 2009. Ms. Ashe was employed at GlaxoSmithKline plc’s legal department where she led legal support for corporate staff functions in the United States and for United States based mergers and acquisitions and equity investments. She has experience in the pharmaceutical and biotechnology industry in business development and as legal counsel for business development transactions and patent matters. She is an Observer on the Boards of Aileron and Alios. She had been Independent Director of Aptose Biosciences Inc. since August 15, 2018 until June 16, 2025. Ms. Ashe has been an Independent Director of Elicio Therapeutics Inc. since August 2020. Ms. Ashe is a registered patent Attorney with the USPTO. She holds a J.D. from the Villanova University School of Law and a B.S. degree in Biology from the Pennsylvania State University. She holds law degree from Villanova University School of Law.

Positions